NCT00823355View on ClinicalTrials.gov

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

August 31, 2013

Conditions
Recurrent or Refractory T/NK-cell Malignancies
Interventions
DRUG

forodesine hydrochloride

Cohort 1: 100mg / body (1 x 100mg tablet once daily)

DRUG

forodesine hydrochloride

Cohort 2: 200mg / body (2 x 100mg tablets once daily)

DRUG

forodesine hydrochloride

Cohort 3: 300mg / body (3 x 100mg tablets once daily)

DRUG

forodesine hydrochloride

Cohort 4: 400mg / body (4 x 100mg tablets once daily)

Trial Locations (3)

Unknown

Investigational Site, Nagoya

Investigational Site, Nagasaki

Investigational Site, Cyuo

Sponsors

Lead Sponsor

Mundipharma K.K.
All Listed Sponsors
lead

Mundipharma K.K.

INDUSTRY

NCT00823355 - Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies | Biotech Hunter | Biotech Hunter